{"id":31859,"date":"2012-09-17T19:07:17","date_gmt":"2012-09-17T23:07:17","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=31859"},"modified":"2012-09-17T19:07:17","modified_gmt":"2012-09-17T23:07:17","slug":"resuming-warfarin-after-a-gi-bleed-benefits-appear-to-outweigh-the-risks","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2012\/09\/17\/resuming-warfarin-after-a-gi-bleed-benefits-appear-to-outweigh-the-risks\/","title":{"rendered":"Resuming Warfarin After a GI Bleed: Benefits Appear to Outweigh the Risks"},"content":{"rendered":"<p>Many patients who&#8217;ve had a warfarin-associated gastrointestinal bleed can safely resume warfarin therapy soon after the bleeding event, according to an industry-funded, retrospective <a href=\"http:\/\/archinte.jamanetwork.com\/article.aspx?articleid=1358544\">study in the <em>Archives of Internal Medicine<\/em><\/a>.<\/p>\n<p>Researchers identified some 440 adults who experienced a GI bleed while taking warfarin; nearly 60% either stayed on warfarin continuously or resumed treatment within about a week (median time to retreatment, 4 days). Compared with patients who did not restart warfarin, those who continued or resumed treatment had a significantly lower 90-day incidence of thrombosis (0.4% vs. 5.5%) and death (6% vs. 20%). The most common causes of death were cancer, infection, and cardiac disease.<\/p>\n<p>Patients who continued or restarted warfarin did have more recurrent GI bleeds (10% vs. 6%), but this difference did not achieve statistical significance. None of the recurrent bleeds were fatal.<\/p>\n<p><a href=\"http:\/\/archinte.jamanetwork.com\/article.aspx?articleid=1358547\"><em>Archives<\/em> commentators<\/a> conclude: &#8220;We believe that most patients with warfarin-associated GI bleeding and indications for continued long-term antithrombotic therapy should resume anticoagulation within the first week following the hemorrhage.&#8221;<\/p>\n<p><em>Reprinted with permission from<\/em> <a href=\"http:\/\/firstwatch.jwatch.org\/\">Physician&#8217;s First Watch<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Many patients who&#8217;ve had a warfarin-associated gastrointestinal bleed can safely resume warfarin therapy soon after the bleeding event, according to an industry-funded, retrospective study in the Archives of Internal Medicine. Researchers identified some 440 adults who experienced a GI bleed while taking warfarin; nearly 60% either stayed on warfarin continuously or resumed treatment within about [&hellip;]<\/p>\n","protected":false},"author":577,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495],"tags":[],"class_list":["post-31859","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/31859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/577"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=31859"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/31859\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=31859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=31859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=31859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}